Qian Meng, Feng Shuo, Zhou Hangcheng, Chen Lijie, Wang Song, Zhang Kaiguang
Department of Gastroenterology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Graduate School, Bengbu Medical College, Bengbu, Anhui, China.
Therap Adv Gastroenterol. 2022 Nov 21;15:17562848221138156. doi: 10.1177/17562848221138156. eCollection 2022.
Endoscopic submucosal dissection (ESD) has been a preferred treatment option for superficial esophageal squamous cell carcinoma (SESCC).
To compare the outcomes of ESD and esophagectomy in the treatment of SESCC, especially for lesions invading muscularis mucosa or submucosa (pT1a-MM/T1b).
We retrospectively analyzed data from patients with SESCC who underwent ESD or esophagectomy between 2015 and 2021.
After propensity score matching, overall survival (OS), disease-specific survival (DSS), recurrence-free survival (RFS), and treatment-related events were compared between the ESD and esophagectomy groups. Furthermore, we performed a Cox regression analysis to identify factors associated with survival.
OS and DSS were significantly higher in the ESD group ( = 508) than that in the esophagectomy group ( = 466). After matching, 404 patients (202 per group) were included in the study. No significant differences were found between the ESD and esophagectomy groups in OS ( = 0.566), RFS ( = 0.586), and DSS ( = 0.912). The ESD group showed less blood loss, shorter procedure duration and hospital stay, lower hospital cost, and fewer adverse events. However, a lower R0 resection rate was observed in the ESD group compared to the esophagectomy group. Subgroup analysis showed comparable survival outcomes between the two groups. In Cox regression analysis, age was the independent factor associated with OS.
In the treatment of SESCC, ESD showed sufficient safety and advantages. Even for pT1a-MM/pT1b SESCC, ESD may be an alternative treatment to esophagectomy.
内镜黏膜下剥离术(ESD)一直是浅表性食管鳞状细胞癌(SESCC)的首选治疗方法。
比较ESD和食管切除术治疗SESCC的效果,尤其是对于侵犯黏膜肌层或黏膜下层(pT1a-MM/T1b)的病变。
我们回顾性分析了2015年至2021年间接受ESD或食管切除术的SESCC患者的数据。
在倾向评分匹配后,比较ESD组和食管切除组的总生存期(OS)、疾病特异性生存期(DSS)、无复发生存期(RFS)和治疗相关事件。此外,我们进行了Cox回归分析以确定与生存相关的因素。
ESD组(n = 508)的OS和DSS显著高于食管切除组(n = 466)。匹配后,404例患者(每组202例)纳入研究。ESD组和食管切除组在OS(P = 0.566)、RFS(P = 0.586)和DSS(P = 0.912)方面未发现显著差异。ESD组失血更少、手术时间和住院时间更短、住院费用更低且不良事件更少。然而,与食管切除组相比,ESD组的R0切除率较低。亚组分析显示两组的生存结果相当。在Cox回归分析中,年龄是与OS相关的独立因素。
在SESCC的治疗中,ESD显示出足够的安全性和优势。即使对于pT1a-MM/pT1b SESCC,ESD也可能是食管切除术的替代治疗方法。